Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharm, has received Fast Track designation from the U.S. FDA for NG-350A, a treatment for mismatch repair-proficient locally advanced rectal cancer. This designation is significant as it expedites the development and approval process for drugs addressing unmet medical needs. NG-350A, developed in collaboration with Akamis Bio Ltd., is currently undergoing Phase Ib clinical trials and has shown promising results in safety and efficacy. This advancement strengthens Sihuan Pharmaceutical’s position in the oncology sector and highlights its commitment to addressing major clinical needs.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd., founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, is an international medical aesthetic and pharmaceutical company. It focuses on innovation with a robust research and development platform, a diverse global product pipeline, and a comprehensive production and sales system. The company aims to become a leading entity in the medical aesthetics and biopharmaceutical sectors in China.
Average Trading Volume: 75,810,188
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.25B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.